[1]干 娜,王耀斐,蔺兆星,等.转移因子胶囊和草分枝杆菌F.U.36注射液联合治疗女性复发性生殖器疱疹疗效观察[J].新乡医学院学报,2020,37(3):282-285.[doi:10.7683/xxyxyxb.2020.03.020]
 GAN Na,WANG Yaofei,LIN Zhaoxing,et al.Effect of transfer factor capsule combined with Mycobacterium phlei F.U.36 injection on female recurrent genital herpes[J].Journal of Xinxiang Medical University,2020,37(3):282-285.[doi:10.7683/xxyxyxb.2020.03.020]
点击复制

转移因子胶囊和草分枝杆菌F.U.36注射液联合治疗女性复发性生殖器疱疹疗效观察
分享到:

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
37
期数:
2020年3
页码:
282-285
栏目:
临床研究
出版日期:
2020-03-12

文章信息/Info

Title:
Effect of transfer factor capsule combined with Mycobacterium phlei F.U.36 injection on female recurrent genital herpes
作者:
干 娜王耀斐蔺兆星刘 乐
(陕西省地方病防治研究所,陕西省皮肤性病防治所医院,陕西 西安 710003)
Author(s):
GAN NaWANG YaofeiLIN ZhaoxingLIU Le
(Shaanxi Provincial Institute for Endemic Disease Control,the Hospital of Shaanxi Provincial Institute for Dermatology and Venereology,Xi′an 710003,Shaanxi Province,China)
关键词:
复发性生殖器疱疹转移因子胶囊草分枝杆菌F.U.36注射液免疫功能炎症反应
Keywords:
recurrent genital herpestransfer factor capsuleMycobacterium phlei F.U.36 injectionimmune functioninflammatory reaction
分类号:
R752.1
DOI:
10.7683/xxyxyxb.2020.03.020
文献标志码:
A
摘要:
目的 探讨转移因子胶囊和草分枝杆菌F.U.36注射液联合治疗女性复发性生殖器疱疹(RGH)的临床效果。方法 选择2015年1月至2017年10月陕西省地方病防治研究所收治的248例女性RGH患者为研究对象,根究治疗方法分为观察组和对照组,每组124例。对照组患者给予草分枝杆菌F.U.36注射液治疗,观察组患者给予转移因子胶囊和草分枝杆菌F.U.36注射液联合治疗。分别于治疗前后检测2组患者外周血CD3+、CD4+、CD4+/CD8+水平及血清白细胞介素-8(IL-8)、白细胞介素-10(IL-10)、单核细胞趋化蛋白1(MCP-1)水平,采用健康调查简表(SF-36)评价患者生活质量,采用视觉模拟评分法(VAS)评估患者自觉疼痛情况;于治疗后6个月评估2组患者临床疗效,并记录RGH复发及不良反应情况。结果 2组患者治疗前CD3+、CD4+、CD4+/CD8+水平比较差异无统计学意义(P>0.05); 2组患者治疗后CD3+、CD4+、CD4+/CD8+水平显著高于治疗前(P<0.05);治疗后,观察组患者CD3+、CD4+、CD4+/CD8+水平显著高于对照组(P<0.05)。2组患者治疗前血清IL-8、IL-10、MCP-1水平比较差异无统计学意义(P>0.05); 2组患者治疗后血清IL-8、IL-10、MCP-1水平显著低于治疗前(P<0.05);治疗后,观察组患者血清IL-8、IL-10、MCP-1水平显著低于对照组(P<0.05)。2组患者治疗前VAS评分、SF-36评分比较差异无统计学意义(P>0.05);2组患者治疗后VAS评分显著低于治疗前,SF-36评分显著高于治疗前(P<0.05);治疗后,观察组患者VAS评分显著低于对照组,SF-36评分显著高于对照组(P<0.05)。观察组和对照组治疗总有效率分别为93.55%(116/124)、79.03%(98/124),观察组患者总有效率高于对照组(χ2=11.043,P<0.05);观察组和对照组患者复发率分别为7.76%(9/116)、27.55%(27/98),观察组患者复发率低于对照组(χ2=14.872,P<0.05)。观察组和对照组患者不良反应发生率分别为8.06%(10/124)、5.65%(7/124),2组患者不良反应发生率比较差异无统计学意义(χ2=0.568,P>0.05)。结论 转移因子胶囊、草分枝杆菌F.U.36注射液联合治疗女性RGH效果显著,可有效改善患者免疫功能,缓解炎症反应及疼痛程度,提高生活质量。
Abstract:
Objective To investigate the clinical effect of transfer factor capsule combined with Mycobacterium phlei F.U.36 injection on female recurrent genital herpes (RGH).Methods A total of 248 women with RGH from January 2015 to October 2017 in Shaanxi Provincial Institute for Endemic Disease Control were selected as the research subjects.The patients were divided into observation group and control group,with 124 cases in each group.The patients in the control group were treated with Mycobacterium phlei F.U.36 injection,and the patients in the observation group were treated with transfer factor capsule and Mycobacterium phlei F.U.36 injection.Before and after treatment,the levels of CD3+,CD4+,CD4+/CD8+ in peripheral blood and the levels of serum interleukin-8 (IL-8),interleukin-10 (IL-10),monocyte chemoattractant protein-1 (MCP-1) of patients in the two groups were detected;the quality of life of the patients was evaluated by the 36-item short form health survey(SF-36);and the conscious pain was evaluated by visual analogue scales(VAS).The patients in the two groups were evaluated six months after treatment The recurrence and adverse reactions of RGH were recorded.The clinical effect of patients in the two groups were evaluated at six months after treatment,and the RGH recurrence and adverse reactions were recorded.Results There was no significant difference in the levels of CD3+,CD4+ and CD4+/CD8+ between the two groups before treatment (P>0.05).The levels of CD3+,CD4+ and CD4+/CD8+ after treatment were significantly higher than those before treatment in the two groups (P<0.05).The levels of CD3+,CD4+ and CD4+/CD8+ in the observation group were significantly higher than those in the control group after treatment (P<0.05).There was no significant difference in the levels of serum IL-8,IL-10 and MCP-1 between the two groups before treatment (P>0.05).The levels of serum IL-8,IL-10 and MCP-1 after treatment were significantly lower than those before treatment in the two groups (P<0.05).The levels of serum IL-8,IL-10 and MCP-1 in the observation group were significantly lower than those in the control group after treatment (P<0.05).There was no significant difference in VAS score and SF-36 score between the two groups before treatment (P>0.05).The VAS score after treatment was significantly lower than that before treatment,and the SF-36 score after treatment was significantly higher than that before treatment in the two groups (P<0.05).After treatment,the VAS score in the observation group was significantly lower than that in the control group,and the SF-36 score in the observation group was significantly higher than that in the control group (P<0.05).The total effective rate in the observation group and the control group was 93.55% (116/124) and 79.03% (98/124),respectively.The total effective rate in the observation group was higher than that in the control group (χ2=11.043,P<0.05).The recurrence rate of RGH in the observation group and the control group was 7.76% (9/116) and 27.55% (27/98),respectively.The recurrence rate of RGH in the observation group was lower than that in the control group (χ2=14.872,P<0.05).The incidence of adverse reactions in the observation group and the observation group was 8.06% (10/124) and 5.65% (7/124),respectively.There was no significant difference in the incidence of adverse reactions between the two groups (χ2=0.568,P>0.05).Conclusions The combination of transfer factor capsule and Mycobacterium phlei F.U.36 injection in the treatment of female RGH has a significant effect,which can effectively improve the immune function,alleviate the inflammatory reaction and pain,and improve the quality of life.

参考文献/References:

[1] 李雪.生殖器疱疹患者HSV-1和HSV-2感染情况检测及其流行特点分析[J].中国实用医药,2016,11(2):103-104.
[2] 汪玉霞,栗敏,白桦.膦甲酸钠联合阿昔洛韦对复发性生殖器疱疹患者免疫功能的影响[J].中国计划生育学杂志,2017,25(7):467-470.
[3] US PREVENTIVE SERVICE TASK FORE.Serologic screening for genital herpes infection:US preventive services task force recommendation statement[J].JAMA,2016,316(23):2525-2530.
[4] 曾东武,谢毅宇,吴惠健,等.香菇多糖联合伐昔洛韦治疗复发性生殖器疱疹的疗效及其对T细胞亚群的影响[J].海南医学,2016,27(21):3525-3527.
[5] 蔡美玲.盐酸伐昔洛韦片联合膦甲酸钠对复发性生殖器疱疹患者外周血免疫平衡调节作用及疗效观察[J].中国药师,2016,19(1):92-93.
[6] 王春燕,刘玮,渠媛,等.阿昔洛韦、微波联合穴位注射对女性复发性生殖器疱疹患者炎性因子和免疫功能的影响[J].现代中西医结合杂志,2016,25(14):1515-1517.
[7] ANTOINE T E,HADIGAL S R,YAKOUB A M,et al.Intravaginal zinc oxide tetrapod nanoparticles as novel immunoprotective agents against genital herpes[J].J Immunol,2016,196(11):4566-4575.
[8] 马璇雯.穴位注射联合中药贴敷对支气管哮喘大鼠的作用机制研究[D].石家庄:河北医科大学,2017.
[9] LIANG Y,ZHANG J,YANG Y,et al.Immunogenicity and therapeutic effects of recombinant Ag85AB fusion protein vaccines in mice infected with Mycobacterium tuberculosis[J].Vaccine,2017,35(32):3995-4001.
[10] 李光艳,夏铵冬,郑自明.应用转移因子胶囊与抗结核药物联合治疗老年肺结核的临床疗效评价[J].实用老年医学,2015,29(2):145-147.
[11] STANOJEVIV S,GRAHAM B L,COOPER B G,et al.Official ERS technical standards:global lung function initiative reference values for the carbon monoxide transfer factor for Caucasians[J].Eur Respir J,2017,50(3):1700010.
[12] 齐心欣,念其银,顾忠民.雾化吸入灭活草分枝杆菌对脓毒症肺损伤大鼠白细胞介素17F的影响[J].海峡药学,2018,30(1):28-31.
[13] 李慧,吴云.趋化因子及黏附因子在重症实验性自身免疫性神经炎模型中作用的研究[J].哈尔滨医科大学学报,2016,50(5):407-410.
[14] 张如峰,杨桂文,安利国.趋化因子及其受体在炎症中作用的研究进展[J].国际免疫学杂志,2012,35(3):191-196.
[15] 宋贾玲,蓝善辉,周萍,等.转移因子对复发性生殖器疱疹患者免疫状态及趋化因子的影响观察[J].中国性科学,2017,26(3):75-78.

更新日期/Last Update: 2020-03-05